Medscape is available in 5 Language Editions – Choose your Edition here.



  • Author: Hisham Nazer, MB, BCh, FRCP, , DTM&H; Chief Editor: Burt Cagir, MD, FACS  more...
Updated: Feb 15, 2016


Giardiasis is a major diarrheal disease found throughout the world. The flagellate protozoan Giardia intestinalis­­ (previously known as G lamblia), its causative agent, is the most commonly identified intestinal parasite in the United States and the most common protozoal intestinal parasite isolated worldwide.[1, 2, 3, 4] Infection is more common in children than in adults.[5, 6]

G intestinalis can cause asymptomatic colonization or acute or chronic diarrheal illness. The organism has been found in as many as 80% of raw water supplies from lakes, streams, and ponds and in as many as 15% of filtered water samples.[7, 8] It is a common cause of chronic diarrhea and growth retardation in children in developing countries.

Giardiasis usually represents a zoonosis with cross-infectivity between animals and humans. Giardiaintestinalis has been isolated from the stools of beavers, dogs, cats, and primates. Beavers may be an important reservoir host for G intestinalis.[9, 10, 11] Other Giardia species include G muris in rodents; G agilis in amphibians; G psittaci and G ardeae in birds; and G microti in voles and muskrats.[12, 13, 14]

Giardia species are endemic in areas of the world that have poor sanitation. In developing countries, the disease is an important cause of morbidity. Water-borne and food-borne outbreaks are common. Because ingestion of as few as 10 Giardia cysts may be sufficient to cause infection, giardiasis is common in daycare center attendees and institutionalized patients in developed countries. G intestinalis is a particularly significant pathogen for people with malnutrition, immunodeficiencies, or cystic fibrosis.

High-risk groups for giardiasis include travelers to highly endemic areas, immunocompromised individuals, and certain sexually active homosexual men. Cyst passage rates as high as 20% have been reported among certain groups of sexually active homosexual men. These individuals were frequently symptomatic.[9, 15]

The traditional basis of diagnosis is identification of Giardia intestinalis trophozoites or cysts in the stool of infected patients via a stool ova and parasite (O&P) examination. Stool antigen enzyme-linked immunosorbent assays also are available. (See Workup.) Standard treatment for giardiasis consists of antibiotic therapy. Metronidazole is the most commonly prescribed antibiotic for this condition; however, tinidazole is now approved in the United States and is considered a first-line agent outside the United States. (See Treatment.)

A G intestinalis cyst is seen in the image below.

A Giardia intestinalis cyst. A Giardia intestinalis cyst.

See Common Intestinal Parasites and 5 Cases of Food Poisoning: Can You Identify the Pathogen?, Critical Images slideshows, to help make an accurate diagnosis.

Historical background

Giardia was originally observed by von Leeuwenhoek in 1681, in his own diarrheal stool, and was described by Vilem Dusan Lambl in 1859 and by Alfred Giard in 1895. The organism’s previous name, honoring the contributions of Giard and Lambl, was bestowed in 1915.

Although G intestinalis was the first protozoan parasite described, its role as a pathogenic organism was not recognized until the 1970s, after community outbreaks and after the appearance of the disease in travelers returning from endemic regions. Prior to that time, the organism was thought to be a harmless commensal organism of the intestine.



Infection with Giardia intestinalis most often results from fecal-oral transmission or ingestion of contaminated water. Contaminated food is a less common etiology. Person-to-person spread is common, with 25% of family members with infected children themselves becoming infected.

Most infections are asymptomatic. The rate of symptomatic infection in the natural setting varies from 5-70%. Giardia is found in healthy people in endemic areas, and asymptomatic carriage with excretion of high numbers of cysts in stools is common.

Predisposing factors to symptomatic infection include hypochlorhydria, various immune system deficiencies, blood group A, and malnutrition. The incubation period averages 1-2 weeks, with a mean of 9 days. The average duration of symptoms in all ages ranges from 3-10 weeks.

Giardia life cycle

Giardia has one of the simplest life cycles of all human parasites. The life cycle is composed of 2 stages: (1) the trophozoite (see the first image below), which exists freely in the human small intestine; and (2) the cyst, which is passed into the environment. No intermediate hosts are required.

Upon ingestion of the cyst (see the second image below), contained in contaminated water or food, excystation occurs in the stomach and the duodenum in the presence of acid and pancreatic enzymes. The trophozoites pass into the small bowel where they multiply rapidly, with a doubling time of 9-12 hours. As trophozoites pass into the large bowel, encystation occurs in the presence of neutral pH and secondary bile salts. Cysts are passed into the environment, and the cycle is repeated.

Giardia lamblia, cyst form. Giardia lamblia, cyst form.
Giardia lamblia trophozoites in culture. Giardia lamblia trophozoites in culture.

The trophozoite form of G lamblia is teardrop-shaped and measures 9-21 micrometers long by 5-15 micrometers wide. The trophozoite has a convex dorsal surface and a flat ventral surface that contains the ventral disk, a rigid cytoskeleton composed of microtubules and microribbons. The trophozoite also contains 4 pairs of flagella, directed posteriorly, that aid the parasite in moving. Two symmetric nuclei with prominent karyosomes produce the characteristic facelike image that appears on stained preparations.

The ventral disk, which is often referred to as the sucking or adhesive disk, provides the parasite with powerful adhesion, catching, and holding abilities. In the murine model of giardiasis, the ventral disk adhesion imprints are marked but less impressive than in the human small intestine. However, this direct injury is an unlikely cause of the more extensive reduction in microvillus surface area, the reduction in disaccharidase activities, and the more pronounced abnormalities of villous architecture that are seen in giardiasis.[16, 17]

The cyst form of the protozoan is smooth-walled and oval in shape, measuring 8-12 micrometers long by 7-10 micrometers wide. As the cyst matures, nuclear division occurs and readies the cyst to release 2 trophozoites upon excystation. Once the host is infected, trophozoites may appear in the duodenum within minutes.[18] Excystation occurs within 5 minutes of exposure of the cysts to an environment with a pH between 1.3 and 2.7.

After infection, the trophozoites attach to the enterocytes via the ventral adhesive disk. This may occur through the presence of lectin on the surface of the trophozoite or through other mechanical means. Encystation is a continuous process during infection.

As the trophozoites encounter neutral pH and/or secondary bile salts, encystation-specific secretory vesicles (ESVs) appear. After 15 hours, cyst wall proteins are visible. Within 24 hours after the appearance of ESVs, the trophozoite is covered with these cyst wall proteins, the form of the cyst has emerged, and new antigenic differences are present.

Mechanism of injury

The mechanisms by which Giardia causes diarrhea and intestinal malabsorption are probably multifactorial and not yet fully elucidated.[16] Postulated mechanisms include damage to the endothelial brush border, enterotoxins, immunologic reactions, and altered gut motility and fluid hypersecretion via increased adenylate cyclase activity.

Adhesion of trophozoites to the epithelium has been demonstrated to cause increased epithelial permeability. Giardia- induced loss of intestinal brush border surface area, villus flattening, inhibition of disaccharidase activities, and eventual overgrowth of enteric bacterial flora appear to be involved in the pathophysiology of giardiasis but have yet to be causatively linked to the disease's clinical manifestations.

Marked or moderate partial villous atrophy in the duodenum and jejunum can be observed in histologic sections from asymptomatic individuals who are infected. In addition to disrupting the mucosal epithelium, effects in the intestinal lumen may contribute to malabsorption and the production of diarrhea.[5, 19] Nevertheless, diarrhea can occur in individuals in the absence of obvious light microscopic changes in small intestinal structure.

Varying degrees of malabsorption of sugars (eg, xylose, disaccharides), fats, and fat-soluble vitamins (eg, vitamins A and E) may contribute to substantial weight loss. The histopathologic response to giardiasis varies and imperfectly correlates with the clinical symptoms.[10, 20]

G intestinalis may release cytopathic substances that damage the intestinal epithelium. Giardia species contain thiol-dependent and thiol-independent proteinases, which may find substrates in the microvillus membrane. In addition, the surface mannose-binding lectin of G intestinalis may contribute to epithelial damage. Whatever the mechanism by which G intestinalis damages villous epithelial cells, the result consistently appears to be an increase in crypt length and crypt cell proliferation.[21]

Enterocytic injury is mediated by activated host T lymphocytes. Pathophysiological activation of lymphocytes is secondary to Giardia -induced disruption of epithelial tight junctions, which, in turn, increases intestinal permeability. Loss of epithelial barrier function is a result of Giardia -induced enterocyte apoptosis.[19, 22, 23]

Epithelial barrier dysfunction in cases with chronic giardiasis is associated with increased rates of enterocyte apoptosis. Consistent with these observations, microarray analyses of the effects of G intestinalis on human CaCo2 cells found that the parasite–host interactions lead to a pronounced up-regulation of genes implicated in the apoptotic cascade and the formation of reactive oxygen species.

Panaro et al demonstrated that Giardia trophozoites induce cell apoptosis by activation of both intrinsic and extrinsic apoptotic pathways, down-regulation of the antiapoptotic protein Bcl-2, and up-regulation of the proapoptotic Bax. These findings suggest a possible role for caspase-dependent apoptosis in the pathogenesis of giardiasis.[24]

Giardia can also prevent the formation of nitric oxide, a compound known to inhibit giardial growth, by consuming local arginine, which effectively removes the substrate needed by enterocytes to produce nitric oxide. This mechanism may contribute to Giardia -induced enterocyte apoptosis because arginine starvation in these cells is known to cause programmed cell death.[16, 25]

G intestinalis is genetically heterogeneous with 8 genetically distinct genotypes or assemblages, designated A-H; assemblages A and B can infect humans. Genotypes vary within group A and B, which could explain why the role of animals in the epidemiology of human infection remains poorly understood.[26, 27] Some strains appear more biologically suitable than other strains. This feature is potentially important in giardiasis pathogenesis.[28, 29] Genotypically diverse isolates of Giardia species may vary in their ability to produce morphologic changes in the small intestine epithelium and to impair fluid, electrolyte, and solute transport.[30]



Giardiasis is caused by the flagellate protozoan Giardia intestinalis (formerly known as G lamblia) . Infection is transmitted through ingestion of infectious G lamblia cysts.[31] The organism is known to have multiple strains with varying abilities to cause disease, and several different strains may be found in one host during infection. The infective dose is low in humans; 10-25 cysts are capable of causing clinical disease in 8 of 25 subjects. Ingestion of more than 25 cysts results in a 100% infection rate.

Person-to-person transmission, often associated with poor hygiene and sanitation, is a primary means of infection. Diaper changing and inadequate hand washing are risk factors for transmission from infected children. Children attending day care centers, as well as day-care workers, have a higher risk of infection secondary to fecal-oral transmission.

Water-borne transmission is responsible for a significant number of epidemics in the United States, generally following ingestion of unfiltered surface water. Giardia cysts retain viability in cold water for as long as 2-3 months. Giardia was implicated in 90 waterborne outbreaks in the United States from 1964-1984, affecting 23,500 persons.

Venereal transmission occurs through fecal-oral contamination. Food-borne epidemics have been reported, most commonly secondary to contamination by infected food-handlers.[32, 33] Pets frequently harbor Giardia in their GI tracts, but they are not thought to be a significant cause of outbreaks in humans.



United States statistics

Giardia remains the parasite most commonly identified in stool specimens. From 1964-1984, G lamblia caused at least 90 water-borne outbreaks of diarrhea, affecting more than 23,000 people. These outbreaks typically involved small water systems using untreated or inadequately treated surface water.

Most water-borne outbreaks in the United States have occurred in western mountain regions (eg, Rocky Mountains, Sierra Nevada, Cascades) where giardiasis must be considered endemic. The incidence of giardiasis is high among individuals who camp and backpack in mountainous Western states. Other groups at increased risk for infection include children, homosexual men, and individuals with immunoglobulin deficiency states (inherited or acquired).

Yoder et al reported that the incidence is greatest in northern states,[34] but this may be related to the differences in individual state surveillance systems and may not necessarily reflect an actual higher incidence.[34] Since water-borne giardiasis outbreaks have been reported in every region in the United States, the diagnosis must be considered anywhere in the country.

Endemic infection occurs most commonly from July through October among children younger than 5 years and adults aged 25-39 years. Carrier rates as high as 30-60% have been documented among children in day care centers, institutions, and on Native American reservations.

The asymptomatic carriage rate in children may be as high as 20% in southern regions and in children younger than 36 months who attend daycare centers. Asymptomatic carriage may persist for several months. Many children with giardiasis are symptomatic, have been shown to spread the disease within their homes, and may contribute to high endemic rates in their communities.[15]

In the 46 states reporting giardiasis, the mean number of cases per 100,000 population varies by state, with a range of 0.1-23.5 cases. Most cases are reported between June and October and are associated with the summer recreational water season and camping.[35]

International statistics

Giardia has a worldwide distribution, occurring in both temperate and tropical regions. It continues to be the most frequently identified human protozoal enteropathogen. Prevalence rates vary from 4-42%. In the industrialized world, overall prevalence rates are 2-5%. In the developing world, G intestinalis infects infants early in life and is a major cause of epidemic childhood diarrhea. Prevalence rates of 15-20% in children younger than 10 years are common.[28, 36]

Giardia is the most common gut parasite in the United Kingdom, and infection rates are especially high in Eastern Europe. Prevalence rates of 0.94-4.66% and 2.41-10.99% have been reported in Italy.[37]

A 2005 study demonstrated a Giardia infection rate of 19.6 per 100,000 population per year in Canada.[38] While the yearly incidence of the disease was stable, a significant seasonal variation was observed, with a peak in late summer to early fall, which correlates with the pattern found in the United States.[38] New Zealand reports more than 30 cases of giardiasis per 100,000 population every year, which is one of the highest among the industrialized countries.[39]

Giardiasis accounts for a relatively small percentage of traveler's diarrhea. It is more likely to be found as the cause of diarrhea that occurs or persists after returning home from travel to developing regions of the world due to its relatively long incubation period and persistent symptoms. Giardia has been identified as the causative agent in a large percentage of cases among travelers to the region of St. Petersburg, Russia, where tap water is the primary source.

The highest prevalence of G intestinalis reached 73.4% in Western Nepal. In Bangladesh, a disparity between health prevention and health spending is observed. The Dhaka study performed within the urban areas had identified G intestinalis in 11% of diarrheal stool specimens.[40]

In Ethiopia, the prevalence has been reported to range from 2.0% to 11.4%.[41] Prevalence of G intestinalis has been reported 13.9% in Côte d'Ivoire.[42]

Race-, sex-, and age-related differences in incidence

Giardiasis does not have any race predilection. Native American populations residing on reservations can have high carrier rates.

Giardiasis is slightly more common in males than in females.[38] A Canadian population study demonstrated infection rates of 21.2 per 100,000 per year versus 17.9 per 100,000 per year for males and females, respectively, resulting in a relative risk of 1.19.[38]

Giardiasis affects people of all ages. Infection is rare during the first 6 months of life in breastfed infants, but infants and young children have an increased susceptibility to giardiasis. Age-specific prevalence of giardiasis continues to rise through infancy and childhood and begins to decline only in adolescence.[15, 43]

Children are particularly at risk for infection through exposure at day-care centers. Many of the epidemics documented over the last 2 decades have originated in day-care centers. Estimates of the prevalence of infection, defined by the presence of cyst passage, have been as high as 20-25% in children younger than 3 years.[44, 45]

According to 2003–2005 data from the Centers for Disease Control and Prevention, the greatest number of reported cases occurred among children aged 1-4 and 5-9 years and adults aged 35-44 years.[34]



The prognosis for patients with giardiasis is generally excellent. Most patients are asymptomatic, and most infections are self-limited. Giardiasis is not associated with mortality except in rare cases of extreme dehydration, primarily in infants or malnourished children.

Several antibiotic agents are available with good efficacy rates to shorten the disease course, although drug resistance has been observed in clinical experience. Untreated, giardiasis can last for weeks.

The parasite persists in the stool.[5, 22] Reinfection is possible.

Weight loss, disaccharidase deficiency, malabsorption, and growth retardation are possible complications.[46, 47]  G intestinalis has been implicated as the chief cause of growth retardation in infected children, even after other diarrhea-causing agents are controlled.[15, 22]

Some patients may experience persistent symptoms (eg, chronic diarrhea/steatorrhea, malabsorption) despite apparently effective antibiotic treatment, although these usually subside over weeks to months.[18, 35, 43] However, Hanevik et al found symptoms consistent with irritable bowel syndrome (IBS) and/or functional dyspepsia in 76 of 82 patients at least 6 months after eradication of Giardia infection.[48] Patients reported bloating, diarrhea, and abdominal pain, which were exacerbated by specific foods or by physical or mental stress. Another study by Hanevik and colleagues associated giardiasis with the presence of IBS and chronic fatigue even 6 years after infection.[49]


Patient Education

Patients and at-risk individuals should be instructed regarding appropriate hygiene methods and signs/symptoms of infection. Emphasis should be placed on measures such as careful hand washing after changing diapers. Day-care workers should use meticulous hygiene and careful hand washing to reduce spread between children and to staff. Personal hygiene education to minimize person-to-person transmission in high-risk settings such as residential institutions is helpful.

Patients should be advised that oral-anal and oral-genital contact increase the risk of venereal transmission.

Hikers and travelers to areas where the disease is endemic should be educated. Before drinking surface water, they should disinfect it by boiling or the use of halogenating compounds (eg, chlorine) or filtration devices.

Contributor Information and Disclosures

Hisham Nazer, MB, BCh, FRCP, , DTM&H Professor of Pediatrics, Consultant in Pediatric Gastroenterology, Hepatology and Clinical Nutrition, University of Jordan Faculty of Medicine, Jordan

Hisham Nazer, MB, BCh, FRCP, , DTM&H is a member of the following medical societies: American Association for Physician Leadership, Royal College of Paediatrics and Child Health, Royal College of Surgeons in Ireland, Royal Society of Tropical Medicine and Hygiene, Royal College of Physicians and Surgeons of the United Kingdom

Disclosure: Nothing to disclose.

Chief Editor

Burt Cagir, MD, FACS Clinical Professor of Surgery, The Commonwealth Medical College; Attending Surgeon, Assistant Program Director, Robert Packer Hospital; Attending Surgeon, Corning Hospital

Burt Cagir, MD, FACS is a member of the following medical societies: American College of Surgeons, American Medical Association, Society for Surgery of the Alimentary Tract

Disclosure: Nothing to disclose.


Manoop S Bhutani, MD Professor, Co-Director, Center for Endoscopic Research, Training and Innovation (CERTAIN), Director, Center for Endoscopic Ultrasound, Department of Medicine, Division of Gastroenterology, University of Texas Medical Branch; Director, Endoscopic Research and Development, The University of Texas MD Anderson Cancer Center

Manoop S Bhutani, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Institute of Ultrasound in Medicine, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Brooks D Cash, MD, FACP Director of Clinical Research, Assistant Professor of Medicine, Division of Gastroenterology, National Naval Medical Center

Brooks D Cash, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Steven C Dronen, MD, FAAEM Chair, Department of Emergency Medicine, LeConte Medical Center

Steven C Dronen, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Michelle Ervin, MD Chair, Department of Emergency Medicine, Howard University Hospital

Michelle Ervin, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, National Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Glenn Fennelly, MD, MPH Director, Division of Infectious Diseases, Lewis M Fraad Department of Pediatrics, Jacobi Medical Center; Clinical Associate Professor of Pediatrics, Albert Einstein College of Medicine

Glenn Fennelly, MD, MPH is a member of the following medical societies: Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Murat Hökelek, MD, PhD Technical Consultant of Parasitology Laboratory, Professor, Department of Clinical Microbiology, Ondokuz Mayis University Medical School, Turkey

Murat Hökelek, MD, PhD is a member of the following medical societies: Turkish Society for Parasitology

Disclosure: Nothing to disclose.

Mark H Johnston, MD Associate Professor of Medicine, Uniformed Services University of Health Sciences; Consulting Staff, Lancaster Gastroenterology Inc

Mark H Johnston, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, and Christian Medical & Dental Society

Disclosure: Nothing to disclose.

Sandeep Mukherjee, MB, BCh, MPH, FRCPC Associate Professor, Department of Internal Medicine, Section of Gastroenterology and Hepatology, University of Nebraska Medical Center; Consulting Staff, Section of Gastroenterology and Hepatology, Veteran Affairs Medical Center

Sandeep Mukherjee, MB, BCh, MPH, FRCPC is a member of the following medical societies: Royal College of Physicians and Surgeons of Canada

Disclosure: Merck Honoraria Speaking and teaching; Ikaria Pharmaceuticals Honoraria Board membership

Michael D Nissen, MBBS, FRACP, FRCPA Associate Professor in Biomolecular, Biomedical Science & Health, Griffith University; Director of Infectious Diseases and Unit Head of Queensland Paediatric Infectious Laboratory, Sir Albert Sakzewski Viral Research Centre, Royal Children's Hospital

Michael D Nissen, MBBS, FRACP, FRCPA is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Pediatric Infectious Diseases Society, Royal Australasian College of Physicians, and Royal College of Pathologists of Australasia

Disclosure: Nothing to disclose.

Andre Pennardt, MD, FACEP, FAAEM, FAWM Clinical Associate Professor of Emergency Medicine, Medical College of Georgia; Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences; Consulting Staff, Departments of Emergency Medicine, Aviation Medicine and Dive Medicine, Womack Army Medical Center

Andre Pennardt, MD, FACEP, FAAEM, FAWM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, Association of Military Surgeons of the US, International Society for Mountain Medicine, National Association of EMS Physicians, Special Operations Medical Association, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Barry J Sheridan, DO Chief Warrior in Transition Services, Brooke Army Medical Center

Barry J Sheridan, DO is a member of the following medical societies: American Academy of Emergency Medicine

Disclosure: Nothing to disclose.

Russell W Steele, MD Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

  1. Daly ER, Roy SJ, Blaney DD, et al. Outbreak of giardiasis associated with a community drinking-water source. Epidemiol Infect. 2010 Apr. 138(4):491-500. [Medline].

  2. Robertson L, Gjerde B, Hansen EF, Stachurska-Hagen T. A water contamination incident in Oslo, Norway during October 2007; a basis for discussion of boil-water notices and the potential for post-treatment contamination of drinking water supplies. J Water Health. 2009 Mar. 7(1):55-66. [Medline].

  3. Eisenstein L, Bodager D, Ginzl D. Outbreak of giardiasis and cryptosporidiosis associated with a neighborhood interactive water fountain--Florida, 2006. J Environ Health. 2008 Oct. 71(3):18-22; quiz 49-50. [Medline].

  4. Nishi L, Baesso ML, Santana RG, Fregadolli P, Falavigna DL, Falavigna-Guilherme AL. Investigation of Cryptosporidium spp. and Giardia spp. in a public water-treatment system. Zoonoses Public Health. 2009 Jun. 56(5):221-8. [Medline].

  5. Hill DR. Giardia lamblia. Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. 2. 6th ed. Philadelphia, Pennsylvania: Churchill Livingstone An Imprint of Elsevier Inc.; 2005. 277: 3198-3203.

  6. Huston CD. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. Feldman M, Friedman LS, Brandt LJ. Intestinal Protozoa. 8th ed. Philadelphia, PA: Saunders, An imprint of Elsevier Inc; 2006. 2: 2420-2423 / 106.

  7. Robertson LJ, Forberg T, Gjerde BK. Giardia cysts in sewage influent in Bergen, Norway 15-23 months after an extensive waterborne outbreak of giardiasis. J Appl Microbiol. 2008 Apr. 104(4):1147-52. [Medline].

  8. Ryu H, Alum A, Mena KD, Abbaszadegan M. Assessment of the risk of infection by Cryptosporidium and Giardia in non-potable reclaimed water. Water Sci Technol. 2007. 55(1-2):283-90. [Medline].

  9. Farthing MJ. Giardiasis. Gastroenterol Clin North Am. 1996 Sep. 25(3):493-515. [Medline].

  10. Sears CL. Giardiasis. Goldman L, Ausiello D. Cecil Medicine. 23rd ed. Philadelphia, PA: Saunders , An Imprint of Elsevier Inc; 2007. 372: 2402-2404.

  11. Monis PT, Thompson RC. Cryptosporidium and Giardia-zoonoses: fact or fiction?. Infect Genet Evol. 2003 Nov. 3(4):233-44. [Medline].

  12. Huang DB, White AC. An updated review on Cryptosporidium and Giardia. Gastroenterol Clin North Am. 2006 Jun. 35(2):291-314, viii. [Medline].

  13. Thompson RC, Palmer CS, O'Handley R. The public health and clinical significance of Giardia and Cryptosporidium in domestic animals. Vet J. 2008 Jul. 177(1):18-25. [Medline].

  14. Ballweber LR, Xiao L, Bowman DD, Kahn G, Cama VA. Giardiasis in dogs and cats: update on epidemiology and public health significance. Trends Parasitol. 2010 Apr. 26(4):180-9. [Medline].

  15. John CC. Giardiasis and Balantidiasis. Kliegman RM, Behrman BE, Jenson HB, Stanton BF. Nelson Textbook of Pediatrics. 279. Philadelphia, PA: Saunders, An imprint of Elsevier Inc; 2007. 18th ed: 1462-1464.

  16. Buret AG. Mechanisms of epithelial dysfunction in giardiasis. Gut. 2007 Mar. 56(3):316-7. [Medline]. [Full Text].

  17. Hill DR. Giardiasis. Issues in diagnosis and management. Infect Dis Clin North Am. 1993 Sep. 7(3):503-25. [Medline].

  18. Hanevik K, Hausken T, Morken MH, et al. Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection. J Infect. 2007 Dec. 55(6):524-30. [Medline].

  19. Buret AG. Pathophysiology of enteric infections with Giardia duodenalius. Parasite. 2008 Sep. 15(3):261-5. [Medline].

  20. Faubert G. Immune response to Giardia duodenalis. Clin Microbiol Rev. 2000 Jan. 13(1):35-54. [Medline]. [Full Text].

  21. Buret AG. Immunopathology of giardiasis: the role of lymphocytes in intestinal epithelial injury and malfunction. Mem Inst Oswaldo Cruz. 2005 Mar. 100 Suppl 1:185-90. [Medline].

  22. Garcia LS. Intestinal Protozoa: Flagellates and Ciliates. Diagnostic Medical Parasitology. 5th ed. Washington, D.C: ASM Press; 2007. 3: 36-49.

  23. Roxstrom-Lindquist K, Palm D, Reiner D, Ringqvist E, Svard SG. Giardia immunity--an update. Trends Parasitol. 2006 Jan. 22(1):26-31. [Medline].

  24. Panaro MA, Cianciulli A, Mitolo V, et al. Caspase-dependent apoptosis of the HCT-8 epithelial cell line induced by the parasite Giardia intestinalis. FEMS Immunol Med Microbiol. 2007 Nov. 51(2):302-9. [Medline].

  25. Liu C, Crawford JM. The Gastrointestinal Tract. Kumar V, Abbas AK, Fausto N. Robbins and Cotran: Pathologic Basis of Disease. 7th ed. Philadelphia: Saunders, An Imprint of Elsevier; 2005. 17: 840. [Full Text].

  26. Sponge H, Caccio SM, van der Giessen JW,ZOOPNET network and partners. Identification of zoonotic genotypes of Giardia duodenalis. PLoS Negl Trop Dis. 2009. 3:e558.

  27. Lebbad M, Petersson I, Karlsson L, et al. Multilocus genotyping of human Giardia isolates suggest limited zoonotic transmission and association between assemblage B and flatulence in children. PLoS Negl TGrop Dis. 2011 Aug. 5(8):e1262.

  28. Caccio SM, Ryan U. Molecular epidemiology of giardiasis. Mol Biochem Parasitol. 2008 Aug. 160(2):75-80. [Medline].

  29. Minvielle MC, Molina NB, Polverino D, Basualdo JA. First genotyping of Giardia lamblia from human and animal feces in Argentina, South America. Mem Inst Oswaldo Cruz. 2008 Feb. 103(1):98-103. [Medline].

  30. Robertson LJ, Forberg T, Hermansen L, Gjerde BK, Langeland N. Molecular characterisation of Giardia isolates from clinical infections following a waterborne outbreak. J Infect. 2007 Jul. 55(1):79-88. [Medline].

  31. Abdul-Wahid A, Faubert G. Characterization of the local immune response to cyst antigens during the acute and elimination phases of primary murine giardiasis. Int J Parasitol. 2008 May. 38(6):691-703. [Medline].

  32. Dawson D. Foodborne protozoan parasites. Int J Food Microbiol. 2005 Aug 25. 103(2):207-27. [Medline].

  33. Fort GG, Mikolich DJ, Policar M. Giardiasis. Ferri FF. Clinical Advisor. 3rd ed. Philadelphia, PA: Mosby, An Imprint of Elsevier; 2009. 358.

  34. Yoder JS, Beach MJ. Giardiasis surveillance--United States, 2003-2005. MMWR Surveill Summ. 2007 Sep 7. 56(7):11-8. [Medline].

  35. Pickering LK. Giardia lamblia (Giardiasis). Long SS. Principles and Practice of Pediatric Infectious Diseases. 3rd ed. Philadelphia, PA: Churchill Livingstone An imprint of Elsevier Inc; 2008. 265: 1241-1245.

  36. Caccio SM, Thompson RC, McLauchlin J, Smith HV. Unravelling Cryptosporidium and Giardia epidemiology. Trends Parasitol. 2005 Sep. 21(9):430-7. [Medline].

  37. Giangaspero A, Berrilli F, Brandonisio O. Giardia and Cryptosporidium and public health: the epidemiological scenario from the Italian perspective. Parasitol Res. 2007 Oct. 101(5):1169-82. [Medline].

  38. Laupland KB, Church DL. Population-based laboratory surveillance for Giardia sp. and Cryptosporidium sp. infections in a large Canadian health region. BMC Infect Dis. 2005 Sep 16. 5:72. [Medline]. [Full Text].

  39. Hoque ME. Conn's Current Therapy. Rakel RE, Bope ET. Giardiasis. 60th ed. Philadelphia, PA: Saunders, An imprint of Elsevier, Inc; 2008. 64: 67/15.

  40. Dib HH, Lu SQ, Wen SF. Prevalence of Giardia lamblia with or without diarrhea in South East, South East Asia and the Far East. Parasitol Res. 2008 Jul. 103(2):239-51. [Medline].

  41. Gelanew T, Lalle M, Hailu A, Pozio E, Caccio SM. Molecular characterization of human isolates of Giardia duodenalis from Ethiopia. Acta Trop. 2007 May. 102(2):92-9. [Medline].

  42. Quihui L, Morales GG, Mendez RO, Leyva JG, Esparza J, Valencia ME. Could giardiasis be a risk factor for low zinc status in schoolchildren from northwestern Mexico? A cross-sectional study with longitudinal follow-up. BMC Public Health. 2010 Feb 20. 10(1):85. [Medline]. [Full Text].

  43. Thompson SC. Giardia lamblia in children and the child care setting: a review of the literature. J Paediatr Child Health. 1994 Jun. 30(3):202-9. [Medline].

  44. Escobedo AA, Almirall P, Alfonso M, Cimerman S, Rey S, Terry SL. Treatment of intestinal protozoan infections in children. Arch Dis Child. 2009 Jun. 94(6):478-82. [Medline].

  45. Jimenez JC, Pinon A, Dive D, Capron M, Dei-Cas E, Convit J. Antibody response in children infected with Giardia intestinalis before and after treatment with Secnidazole. Am J Trop Med Hyg. 2009 Jan. 80(1):11-5. [Medline].

  46. Dizdar V, Gilja OH, Hausken T. Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron. Neurogastroenterol Motil. 2007 Dec. 19(12):977-82. [Medline].

  47. Penrose AS, Wells EV, Aiello AE. Infectious causation of chronic disease: examining the relationship between Giardia lamblia infection and irritable bowel syndrome. World J Gastroenterol. 2007 Sep 14. 13(34):4574-8. [Medline].

  48. Hanevik K, Dizdar V, Langeland N, Hausken T. Development of functional gastrointestinal disorders after Giardia lamblia infection. BMC Gastroenterol. 2009 Apr 21. 9:27. [Medline]. [Full Text].

  49. Hanevik K, Wensaas KA, Rortveit G, et al. Irritable bowel syndrome and chronic fatigue 6 years after Giardia infection: a controlled prospective cohort study. Clin Infect Dis. 2014 Nov 15. 59(10):1394-400. [Medline].

  50. Quihui L, Morales GG, Mendez RO, Leyva JG, Esparza J, Valencia ME. Could giardiasis be a risk factor for low zinc status in schoolchildren from northwestern Mexico? A cross-sectional study with longitudinal follow-up. BMC Public Health. 2010 Feb 20. 10(1):85. [Medline]. [Full Text].

  51. Ouattara M, N'guessan NA, Yapi A, N'goran EK. Prevalence and spatial distribution of Entamoeba histolytica/dispar and Giardia lamblia among schoolchildren in Agboville area (Côte d'Ivoire). PLoS Negl Trop Dis. 2010 Jan 19. 4(1):e574. [Medline]. [Full Text].

  52. Heyworth MF. Diagnostic testing for Giardia infections. Trans R Soc Trop Med Hyg. 2014 Mar. 108 (3):123-5. [Medline].

  53. Nagaty IM, Hegazi MM. Dot-ELISA copro-antigen and direct stool examination in diagnosis of giardiasis patients. J Egypt Soc Parasitol. 2007 Aug. 37(2):641-8. [Medline].

  54. Strand EA, Robertson LJ, Hanevik K, Alvsvag JO, Morch K, Langeland N. Sensitivity of a Giardia antigen test in persistent giardiasis following an extensive outbreak. Clin Microbiol Infect. 2008 Nov. 14(11):1069-71. [Medline].

  55. Mayer CL, Palmer CJ. Evaluation of PCR, nested PCR, and fluorescent antibodies for detection of Giardia and Cryptosporidium species in wastewater. Appl Environ Microbiol. 1996 Jun. 62(6):2081-5. [Medline].

  56. Praesertbun R, Sukthana Y, Popruk S. Real. time PCR: Benefits for Detection of Mild and Symptomatic Giardia Infections. Trop Med Health. 2012 Jun. 40(2):31-5.

  57. Youn S, Kabir M, Haque R, Petri WA Jr. Evaluation of a screening test for detection of giardia and cryptosporidium parasites. J Clin Microbiol. 2009 Feb. 47(2):451-2. [Medline]. [Full Text].

  58. Morken MH, Nysaeter G, Strand EA, Hausken T, Berstad A. Lactulose breath test results in patients with persistent abdominal symptoms following Giardia lamblia infection. Scand J Gastroenterol. 2008. 43(2):141-5. [Medline].

  59. Busatti HG, Santos JF, Gomes MA. The old and new therapeutic approaches to the treatment of giardiasis: where are we?. Biologics. 2009. 3:273-87. [Medline]. [Full Text].

  60. Busatti HG, Vieira AE, Viana JC, et al. Effect of metronidazole analogues on Giardia lamblia cultures. Parasitol Res. 2007 Dec. 102(1):145-9. [Medline].

  61. Monajemzadeh SM, Monajemzadeh M. Comparison of iron and hematological indices in Giardia lamblia infection before and after treatment in 102 children in Ahwaz, Iran. Med Sci Monit. 2008 Jan. 14(1):CR19-23. [Medline].

  62. Escobedo AA, Ballesteros J, Gonzalez-Fraile E, Almirall P. A meta-analysis of the efficacy of albendazole compared with tinidazole as treatments for Giardia infections in children. Acta Trop. 2016 Jan. 153:120-7. [Medline].

  63. Nabarro LE, Lever RA, Armstrong M, Chiodini PL. Increased incidence of nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008-2013. Clin Microbiol Infect. 2015 Aug. 21 (8):791-6. [Medline].

  64. van den Bijllaardt W, Overdevest IT, Buiting AG, Verweij JJ. Rapid clearance of Giardia lamblia DNA from the gut after successful treatment. Clin Microbiol Infect. 2014 Nov. 20 (11):O972-4. [Medline].

  65. Kiser JD, Paulson CP, Brown C. Clinical inquiries. What's the most effective treatment for giardiasis?. J Fam Pract. 2008 Apr. 57(4):270-2. [Medline].

  66. Gardner TB, Hill DR. Treatment of giardiasis. Clin Microbiol Rev. 2001 Jan. 14(1):114-28. [Medline].

  67. Wright JM, Dunn LA, Upcroft P, Upcroft JA. Efficacy of antigiardial drugs. Expert Opin Drug Saf. 2003 Nov. 2(6):529-41. [Medline].

  68. Mahmud MA, Chappell CL, Hossain MM, Huang DB, Habib M, DuPont HL. Impact of breast-feeding on Giardia lamblia infections in Bilbeis, Egypt. Am J Trop Med Hyg. 2001 Sep. 65(3):257-60. [Medline].

  69. Escobedo AA, Cimerman S. Giardiasis: a pharmacotherapy review. Expert Opin Pharmacother. 2007 Aug. 8(12):1885-902. [Medline].

  70. Rayan P, Matthews B, McDonnell PA, Cock IE. Terminalia ferdinandiana extracts as inhibitors of Giardia duodenalis proliferation: a new treatment for giardiasis. Parasitol Res. 2015 Jul. 114 (7):2611-20. [Medline].

  71. Lopez-Romero G, Quintero J, Astiazarán-García H, Velazquez C. Host defences against Giardia lamblia. Parasite Immunol. 2015 Aug. 37 (8):394-406. [Medline].

  72. Astiazaran-García H, Inigo-Figueroa G, Quihui-Cota L, Anduro-Corona I. Crosstalk between zinc status and Giardia infection: a new approach. Nutrients. 2015 Jun 3. 7 (6):4438-52. [Medline].

Giardia lamblia, cyst form.
Giardia lamblia trophozoites in culture.
A Giardia intestinalis cyst.
Giardia intestinalis trophozoites on stool examination from a patient with diarrhea.
Giardia trophozoite
Giardia cyst.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.